



Chimeric Vaccines against Hyper Evolving Pathogens

Guest Editors:

Dr. Yash Gupta

Department of Medicine, Penn
State College of Medicine,
Hershey, PA 17033, USA

Dr. Manish Manish

School of computational and
integrative sciences, Jawaharlal
Nehru University, New Delhi,
India

Deadline for manuscript
submissions:

closed (10 February 2024)

Message from the Guest Editors

Chimeric vaccines can be an effective strategy to combat infectious diseases. The conventional examples include the RTS/S vaccine, which the World Health Organization has recommended for pilot implementation against malaria. The chimeric vaccine approach has also been employed in the FDA-approved vaccine BEXSERO against *Neisseria meningitidis* serogroup B. BEXSERO includes the chimeric fused antigen of Neisserial Heparin Binding Antigen from strain NZ98/254 and accessory protein 953 from strain 2996.

This Special Issue invites high-quality research in the development of chimeric vaccine and epitope variations in the newer strains/serotypes of various pathogens. This will include immune determinant polymorphisms' epidemiology, computational design/screening, mice studies, rational vaccine design and development, immune cell type response and field studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com